Acts as medical expert and leader in interactions with external stakeholders (e.g., regulatory authorities, key opinion leaders, advisory boards, patient advocacy groups), US and global government institutions, internal stakeholders (e.g., Research, Early Clinical Development, Global Medical Affairs, Marketing, HEOR), and internal decision committees. The Executive Medical Director, Immunology & Inflammation, will provide overall clinical scientific leadership for Regenerons Immunology & Inflammation programs, including Dupilumab and Itepekimab, and have responsibility for our clinical development strategy and execution of clinical trials in this area.